Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.

Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P, Trussell C, Schmitt-Graeff A, Landwerlin K, Veelken H, Warmuth M.

Cancer Cell. 2008 Sep 9;14(3):238-49. doi: 10.1016/j.ccr.2008.08.003.

2.

Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.

Chiarenza A, Manetti F, Petricci E, Ruat M, Naldini A, Taddei M, Carraro F.

PLoS One. 2016 Mar 2;11(3):e0149919. doi: 10.1371/journal.pone.0149919. eCollection 2016.

3.

Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients.

Long B, Zhu H, Zhu C, Liu T, Meng W.

J Exp Clin Cancer Res. 2011 Jan 16;30:8. doi: 10.1186/1756-9966-30-8.

4.

Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.

Cea M, Cagnetta A, Cirmena G, Garuti A, Rocco I, Palermo C, Pierri I, Reverberi D, Nencioni A, Ballestrero A, Gobbi M, Carella AM, Patrone F.

Leuk Lymphoma. 2013 Feb;54(2):342-52. doi: 10.3109/10428194.2012.708752. Epub 2012 Sep 5.

PMID:
22762548
5.

Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells.

Babashah S, Sadeghizadeh M, Hajifathali A, Tavirani MR, Zomorod MS, Ghadiani M, Soleimani M.

Int J Cancer. 2013 Aug 1;133(3):579-89. doi: 10.1002/ijc.28043. Epub 2013 Mar 13.

6.

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL.

Blood. 2012 Feb 9;119(6):1501-10. doi: 10.1182/blood-2010-12-326843. Epub 2011 Dec 19.

7.

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.

Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA, Reya T.

Nature. 2009 Apr 9;458(7239):776-9. doi: 10.1038/nature07737. Erratum in: Nature. 2009 Jul 30;460(7255):652.

8.

Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.

Liao HF, Su YC, Zheng ZY, Jhih Cai C, Hou MH, Chao KS, Chen YJ.

Biomed Pharmacother. 2012 Jul;66(5):378-83. doi: 10.1016/j.biopha.2011.12.008. Epub 2012 Feb 16.

PMID:
22397755
9.

beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.

Hu Y, Chen Y, Douglas L, Li S.

Leukemia. 2009 Jan;23(1):109-16. doi: 10.1038/leu.2008.262. Epub 2008 Sep 25.

PMID:
18818703
10.

Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.

Ng KP, Manjeri A, Lee KL, Huang W, Tan SY, Chuah CT, Poellinger L, Ong ST.

Blood. 2014 May 22;123(21):3316-26. doi: 10.1182/blood-2013-07-511907. Epub 2014 Apr 4.

11.

BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.

Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, Hughes TP, Radich JP, Hochhaus A.

Clin Cancer Res. 2011 Nov 1;17(21):6812-21. doi: 10.1158/1078-0432.CCR-11-0396. Epub 2011 Sep 8.

12.

Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.

Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA.

Blood. 2010 Jul 8;116(1):81-4. doi: 10.1182/blood-2009-10-247437. Epub 2010 Apr 20.

13.

Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.

Xiao M, Ai H, Li T, Rajoria P, Shahu P, Li X.

Biochem Biophys Res Commun. 2016 Apr 15;472(4):610-6. doi: 10.1016/j.bbrc.2016.03.018. Epub 2016 Mar 8.

PMID:
26966074
14.

LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells.

Peng C, Chen Y, Shan Y, Zhang H, Guo Z, Li D, Li S.

PLoS One. 2012;7(6):e38614. doi: 10.1371/journal.pone.0038614. Epub 2012 Jun 4.

15.

The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.

Gustafsson K, Jamalpour M, Trinh C, Kharas MG, Welsh M.

J Hematol Oncol. 2014 Jun 21;7:45. doi: 10.1186/1756-8722-7-45.

16.

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ.

J Clin Invest. 2011 Jan;121(1):396-409. doi: 10.1172/JCI35721. Epub 2010 Dec 13. Erratum in: J Clin Invest. 2011 Mar 1;121(3):1222.

17.

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR.

Sci Transl Med. 2014 Sep 3;6(252):252ra121. doi: 10.1126/scitranslmed.3009073.

18.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.

Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318. Epub 2013 Jul 25.

19.

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.

Herrmann H, Sadovnik I, Cerny-Reiterer S, Rülicke T, Stefanzl G, Willmann M, Hoermann G, Bilban M, Blatt K, Herndlhofer S, Mayerhofer M, Streubel B, Sperr WR, Holyoake TL, Mannhalter C, Valent P.

Blood. 2014 Jun 19;123(25):3951-62. doi: 10.1182/blood-2013-10-536078. Epub 2014 Apr 28.

20.

Hedgehog pathway activation in chronic myeloid leukemia.

Jagani Z, Dorsch M, Warmuth M.

Cell Cycle. 2010 Sep 1;9(17):3449-56. Review.

PMID:
20928937

Supplemental Content

Support Center